Knowledge Sharing ▏Does a Positive PCR Test Always Lead to Clinical Disease?

发布时间:2024-01-30

In many cases, a positive PCR result does not indicate clinical pathogenicity, nor does it imply that the pathogen is the primary causative agent.

Positive for African swine fever and blue ear disease?

Positive PCR for other pathogens?

Summary

When looking for animal disease and pet diagnostic reagents, choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation hotline: 020-66377266 / 135 3988 6748

Ms. Dai

About Weiboxin

Company Headquarters

Guangzhou Weiboxin Biotechnology Co., Ltd. is located in the national-level innovation park—Guangzhou Science City. The company is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for animal epidemics. It has been recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and as a provincial demonstration unit for intellectual property. Additionally, it serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and as an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. The company has been identified by multiple research institutes, including the Entrepreneurship College of Jinan University in Guangdong Province, as an innovative enterprise with strong growth potential. It has also been designated as a “Specialized, Refined, Distinctive, and Innovative” enterprise at both the municipal and provincial levels, receiving awards such as “Most Investment-Valuable Enterprise” and “Annual African Swine Fever and Pig Disease Testing Service Provider.” Furthermore, it holds the Ministry of Agriculture and Rural Affairs’ veterinary drug product approval number: Vet Drug Prod No. 191438923 (African Swine Fever Virus Fluorescent PCR Diagnostic Kit). The company was awarded the Excellence Prize in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, secured the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition, and earned the National Third Prize in the Growth Category of the National Finals of the Nanotechnology Industry Technology Innovation Special Competition within the China Innovation and Entrepreneurship Competition. It has consecutively received the A-Level Tax Credit Honor Certificate, the Four-Star Trademark Brand Certification, and the Two-Integration Management System Assessment Certificate each year. In addition, it has obtained ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, along with more than ten trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic identification test kits (ZL2006). The company has also established a nationwide distribution network covering more than ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Xi’an, Chongqing, Lanzhou, Zhengzhou, and Qingdao.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline; innovation is our soul. Upholding this guiding principle, we will relentlessly strive to become the premier supplier of rapid diagnostic reagents and instruments.

Expert in Rapid Detection and Diagnosis of Animal Epidemics